InvestorsHub Logo
Followers 6
Posts 3891
Boards Moderated 0
Alias Born 01/14/2001

Re: None

Tuesday, 08/01/2006 2:41:48 AM

Tuesday, August 01, 2006 2:41:48 AM

Post# of 82595
Application in latest Press Release:

"SARASOTA, FL -- (MARKET WIRE) -- 07/31/06 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that its subsidiary, DNAPrint Pharmaceuticals, Inc., has completed the development of the so-called "Western blot" method, an analytical procedure that identifies a protein according to its interaction with a specific antibody, a significant step in the development of its PT-401-based proprietary drug to treat anemia.

"The method ensures the identification of PT-401 and meets the requirements of the Food and Drug Administration for a successful Investigational New Drug filing," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics and the Company's DNAPrint Pharmaceuticals subsidiary."

Ann